A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice

BACKGROUND: Tyrosine kinase inhibitors (TKIs) have experienced a tremendous boost in the last decade, where more than 15 small molecule TKIs have been approved by the FDA. Unfortunately, despite their promising clinical successes, a large portion of patients remain unresponsive to these targeted dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Slobbe, Paul, Windhorst, Albert D, Stigter-van Walsum, Marijke, Smit, Egbert F, Niessen, Heiko G, Solca, Flavio, Stehle, Gerd, van Dongen, Guus A M S, Poot, Alex J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385286/
https://www.ncbi.nlm.nih.gov/pubmed/25853020
http://dx.doi.org/10.1186/s13550-015-0088-0

Ejemplares similares

Ejemplares similares